Novo Nordisk’s Teen Pill Win Offers a Rebound, But the Washington Game Is Shifting

Novo Nordisk’s shares staged a dramatic recovery on Friday, surging nearly 7% to close at €35.16, as investors seized on promising clinical data for its oral semaglutide. The Phase 3a PIONEER TEENS trial delivered a 0.83 percentage-point reduction in HbA1c over six months in young patients with Type 2 diabetes — a result that paves the way for broader regulatory filings in the second half of the year.

The rally was a welcome reprieve after a punishing start to 2026. The stock had shed more than 20% since January, with the relative strength index plunging below 18 — territory that typically signals an oversold bounce. Yet even with Friday’s gain, the shares remain nearly 50% below their 52-week high of €70.13, a stark reminder of the headwinds facing Denmark’s largest pharmaceutical company.

A Quiet Overhaul in Washington

Behind the scenes, Novo Nordisk has been recalibrating its political strategy in the US capital — a move that speaks volumes about the regulatory pressures it now faces. On February 1, the company parted ways with Public Strategies Washington, a Democratic-aligned lobbying firm that had spent three-and-a-half years pushing for better Medicare and Medicaid reimbursement for obesity drugs.

The shift is not a retreat from influence-building. Novo Nordisk still spends more than $8 million annually on lobbying, with its in-house team alone reporting nearly $1.3 million in outlays during the first quarter of 2026. What has changed is the political orientation: the company has brought on Republican-leaning shops including S-3 Group LLC, Nickles Group and Ballard Partners, signaling a pivot to the right as the GOP holds sway in Congress.

The catalyst for this strategic overhaul is concrete: the US government selected semaglutide — the active ingredient in both Ozempic and Wegovy — for Medicare price negotiations under the Inflation Reduction Act. Starting in 2027, Ozempic will be capped at $274 per month, down from its current list price of $959. Higher doses of Wegovy will see a Medicare price of $385 monthly.

Novo Nordisk has challenged the pricing regime in court, so far without success. The US Court of Appeals for the Third Circuit dismissed the company’s lawsuit, along with those of other drugmakers. However, the US Chamber of Commerce has filed an amicus brief with the Supreme Court, keeping the legal avenue open — even if a swift ruling remains unlikely.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

The Pre-Dividend Squeeze

The pricing pressure is already baked into management’s outlook. For the full year 2026, Novo Nordisk expects operating profit to decline by 5% to 13%, driven by US price cuts and patent expirations in select markets. CEO Mike Doustdar has called 2026 a “year of price pressure,” pledging to offset the damage through higher sales volumes and bolt-on acquisitions.

To keep shareholders on side, the company is running a DKK 15 billion share buyback program — a familiar tactic to support the stock during turbulent periods.

What the May 6 Numbers Will Reveal

All eyes now turn to the first-quarter earnings report, due on May 6 before the market opens. Analysts are forecasting earnings per share of around $0.85. The numbers will offer the first real test of whether Novo Nordisk can deliver enough volume growth to compensate for shrinking margins.

On the commercial front, the oral formulation of semaglutide for Type 2 diabetes — the Ozempic pill — is slated for a US launch in the second quarter. Meanwhile, the BALANCE model, a voluntary demonstration program offering limited GLP-1 access through Medicare, kicks off in July 2026, with Medicaid enrollment opening in May. It is a stopgap, not a permanent legislative fix.

The May 6 report will provide the clearest picture yet of how deep the pricing damage runs — and whether the volume story can hold the line.